Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × merestinib × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Lymphoid 2 Breast 2 Tumor-Agnostic 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 41 Paclitaxel 40 Gemcitabine 36 Carboplatin 32 Docetaxel 30 Bevacizumab 25 Cisplatin 21 Nivolumab 19 Irinotecan 19 Fluorouracil 18 Erlotinib Hydrochloride 18 Sorafenib 16 Magnetic Resonance Spectroscopy 16 Capecitabine 16 Pemetrexed 15 Cetuximab 15 Afatinib 14 regorafenib 13 olaparib 13 Specimen Handling 13 Leucovorin 13 Oxaliplatin 12 Biopsy 12 trametinib 10 eribulin 9 epothilone B 9 Injections 9 Cyclophosphamide 9 130-nm albumin-bound paclitaxel 9 lenvatinib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01285037 2018-02-20

A Study of LY2801653 in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡